Cargando…

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack...

Descripción completa

Detalles Bibliográficos
Autores principales: Medina, Alejandro, Puig, Noemi, Flores-Montero, Juan, Jimenez, Cristina, Sarasquete, M.-Eugenia, Garcia-Alvarez, María, Prieto-Conde, Isabel, Chillon, Carmen, Alcoceba, Miguel, Gutierrez, Norma C., Oriol, Albert, Rosinol, Laura, Bladè, Joan, Gironella, Mercedes, Hernandez, Miguel T., Gonzalez-Calle, Veronica, Cedena, Maria-Teresa, Paiva, Bruno, San-Miguel, Jesus F., Lahuerta, Juan-Jose, Mateos, Maria-Victoria, Martinez-Lopez, Joaquin, Orfao, Alberto, Gonzalez, Marcos, Garcia-Sanz, Ramon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603393/
https://www.ncbi.nlm.nih.gov/pubmed/33127891
http://dx.doi.org/10.1038/s41408-020-00377-0
_version_ 1783603910711181312
author Medina, Alejandro
Puig, Noemi
Flores-Montero, Juan
Jimenez, Cristina
Sarasquete, M.-Eugenia
Garcia-Alvarez, María
Prieto-Conde, Isabel
Chillon, Carmen
Alcoceba, Miguel
Gutierrez, Norma C.
Oriol, Albert
Rosinol, Laura
Bladè, Joan
Gironella, Mercedes
Hernandez, Miguel T.
Gonzalez-Calle, Veronica
Cedena, Maria-Teresa
Paiva, Bruno
San-Miguel, Jesus F.
Lahuerta, Juan-Jose
Mateos, Maria-Victoria
Martinez-Lopez, Joaquin
Orfao, Alberto
Gonzalez, Marcos
Garcia-Sanz, Ramon
author_facet Medina, Alejandro
Puig, Noemi
Flores-Montero, Juan
Jimenez, Cristina
Sarasquete, M.-Eugenia
Garcia-Alvarez, María
Prieto-Conde, Isabel
Chillon, Carmen
Alcoceba, Miguel
Gutierrez, Norma C.
Oriol, Albert
Rosinol, Laura
Bladè, Joan
Gironella, Mercedes
Hernandez, Miguel T.
Gonzalez-Calle, Veronica
Cedena, Maria-Teresa
Paiva, Bruno
San-Miguel, Jesus F.
Lahuerta, Juan-Jose
Mateos, Maria-Victoria
Martinez-Lopez, Joaquin
Orfao, Alberto
Gonzalez, Marcos
Garcia-Sanz, Ramon
author_sort Medina, Alejandro
collection PubMed
description Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R(2) = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06–0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
format Online
Article
Text
id pubmed-7603393
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76033932020-11-02 Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma Medina, Alejandro Puig, Noemi Flores-Montero, Juan Jimenez, Cristina Sarasquete, M.-Eugenia Garcia-Alvarez, María Prieto-Conde, Isabel Chillon, Carmen Alcoceba, Miguel Gutierrez, Norma C. Oriol, Albert Rosinol, Laura Bladè, Joan Gironella, Mercedes Hernandez, Miguel T. Gonzalez-Calle, Veronica Cedena, Maria-Teresa Paiva, Bruno San-Miguel, Jesus F. Lahuerta, Juan-Jose Mateos, Maria-Victoria Martinez-Lopez, Joaquin Orfao, Alberto Gonzalez, Marcos Garcia-Sanz, Ramon Blood Cancer J Article Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R(2) = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06–0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment. Nature Publishing Group UK 2020-10-30 /pmc/articles/PMC7603393/ /pubmed/33127891 http://dx.doi.org/10.1038/s41408-020-00377-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Medina, Alejandro
Puig, Noemi
Flores-Montero, Juan
Jimenez, Cristina
Sarasquete, M.-Eugenia
Garcia-Alvarez, María
Prieto-Conde, Isabel
Chillon, Carmen
Alcoceba, Miguel
Gutierrez, Norma C.
Oriol, Albert
Rosinol, Laura
Bladè, Joan
Gironella, Mercedes
Hernandez, Miguel T.
Gonzalez-Calle, Veronica
Cedena, Maria-Teresa
Paiva, Bruno
San-Miguel, Jesus F.
Lahuerta, Juan-Jose
Mateos, Maria-Victoria
Martinez-Lopez, Joaquin
Orfao, Alberto
Gonzalez, Marcos
Garcia-Sanz, Ramon
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
title Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
title_full Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
title_fullStr Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
title_full_unstemmed Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
title_short Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
title_sort comparison of next-generation sequencing (ngs) and next-generation flow (ngf) for minimal residual disease (mrd) assessment in multiple myeloma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603393/
https://www.ncbi.nlm.nih.gov/pubmed/33127891
http://dx.doi.org/10.1038/s41408-020-00377-0
work_keys_str_mv AT medinaalejandro comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT puignoemi comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT floresmonterojuan comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT jimenezcristina comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT sarasquetemeugenia comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT garciaalvarezmaria comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT prietocondeisabel comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT chilloncarmen comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT alcocebamiguel comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT gutierreznormac comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT oriolalbert comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT rosinollaura comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT bladejoan comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT gironellamercedes comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT hernandezmiguelt comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT gonzalezcalleveronica comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT cedenamariateresa comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT paivabruno comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT sanmigueljesusf comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT lahuertajuanjose comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT mateosmariavictoria comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT martinezlopezjoaquin comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT orfaoalberto comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT gonzalezmarcos comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma
AT garciasanzramon comparisonofnextgenerationsequencingngsandnextgenerationflowngfforminimalresidualdiseasemrdassessmentinmultiplemyeloma